Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Article   |    
Evaluating the Effectiveness of the New Antidepressants
Roberto A. Dominguez
Psychiatric Services 1983; doi:
View Author and Article Information

University of Miami School of Medicine; Department of Psychiatry (D4-12), 1550 N.W. 10th Avenue, Room 208, Miami, Florida 33136

1983 by the American Psychiatric Association

text A A A
PDF of the full text article.

A review of the many controlled studies with these compounds shows two common problems in clinical psychopharmacology. The first problem is that many large studies, otherwise sound in design, have used heterogeneous populations in their samples, so that the results have been predictably obscured. Fortunately, most research studies today are designed to obtain a more homogeneous symptomatic population by the use of diagnostic criteria from DSM-III (21) or other research sources.The second problem is that rating tools used for measuring therapeutic change are often obsolete. This problem is more difficult to address, and no acceptable solutions appear close at hand. Because of these two flaws in study design, it is possible that there are consistent significant differences in the comparative efficacy of these compounds that have gone undetected.Superficially it appears as though the availability of these four new drugs adds little strength to the therapeutic armamentarium of the mental health professional. Certainly no decisive progress has been made in therapeutic effectiveness, and the verdict is still uncertain regarding the accuracy of the claims of faster onset of action. Yet some of these drugs do offer a more benign cardiovascular profile and fewer anticholinergic side effects. In addition, the development of trazodone paves the way toward other atypical antidepressants currently undergoing ambitious and, we hope, fruitful research.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles
Depression and chronic kidney disease: A review for clinicians. Aust N Z J Psychiatry Published online Mar 21, 2014.;